Insulin-like Growth Factor 1

Insulin-like Growth Factor 1 (IGF-1) is a peptide hormone primarily produced in the liver and plays a crucial role in growth and development. Researchers primarily study IGF-1 for its involvement in various physiological processes, including glucose metabolism, muscle hypertrophy, and tissue regeneration. Key findings indicate that IGF-1 signaling is linked to the regulation of glucose uptake in colorectal cancer cells and is essential for muscle protein synthesis and regeneration, while also influencing cardiac adaptation to stress through immune cell interactions. Current research continues to explore the molecular mechanisms of IGF-1 in different pathological conditions, highlighting its potential relevance in therapeutic strategies for muscle atrophy and tendon healing. Despite promising preclinical results, clinical evidence indicates that the effectiveness of IGF-1 in enhancing tissue repair remains to be fully understood.

Insulin-like Growth Factor 1 (IGF-1), also known as Somatomedin C or Mecasermin, is an endogenous peptide hormone primarily produced in the liver, although it is also synthesized in other tissues. It belongs to the chemical class of growth factors and shares structural similarity with insulin. IGF-1 plays a crucial role in growth and development, acting as a mediator of growth hormone effects. Researchers have extensively studied IGF-1's involvement in various physiological processes, including glucose metabolism, muscle hypertrophy and atrophy, cardiac growth, and tendon regeneration. In colorectal cancer, IGF-1 signaling is implicated in glucose metabolism and the Warburg effect, while in skeletal muscle, it regulates protein synthesis and degradation pathways. IGF-1 exerts its effects through binding to the IGF-1 receptor (IGF-1R), activating intracellular signaling cascades such as the PI3K/Akt/mTOR and MAPK pathways. These pathways influence cellular processes like protein synthesis, cell growth, and survival. Pharmacokinetically, endogenous IGF-1 has a circulating half-life of approximately 70 minutes, with its metabolism primarily occurring in the liver. The bioavailability of IGF-1 can vary depending on the route of administration, with subcutaneous and intravenous routes being more common in clinical settings. Clinically, IGF-1 is used in specific conditions such as growth failure in children with severe primary IGF-1 deficiency. It is subject to regulatory oversight, with its use in sports being prohibited by the World Anti-Doping Agency due to its performance-enhancing potential.

IGF-1 acts on the IGF-1 receptor (IGF-1R), triggering the activation of the PI3K/Akt/mTOR and MAPK signaling pathways. This activation leads to increased protein synthesis, cell growth, and inhibition of apoptosis, contributing to its anabolic effects.

Insulin-like Growth Factor 1 (IGF-1) primarily exerts its effects through the IGF-1 receptor (IGF-1R), activating the PI3K/Akt/mTOR and Raf/MAPK signaling pathways. This leads to enhanced glucose uptake, protein synthesis, and inhibition of muscle atrophy by suppressing FoxO transcription factors and E3 ubiquitin ligases. The precise mechanisms by which IGF-1 regulates these processes, particularly in contexts like colorectal cancer and tendon healing, remain incompletely understood.

Current evidence is limited regarding the specific molecular mechanisms by which IGF-1 influences glucose metabolism in colorectal cancer, particularly in relation to the Warburg effect and its interactions with other signaling pathways. Further research is needed to elucidate the role of IGF-1 in muscle atrophy and hypertrophy, especially through the regulation of autophagy and miRNA involvement in various pathological conditions. Additionally, larger randomized controlled trials are necessary to better understand the efficacy of IGF-1 in tendon regenerative therapies and to identify the optimal conditions for its clinical application, as current findings have shown limited success in human trials.